Patents by Inventor Vivek P. Singh

Vivek P. Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230030961
    Abstract: A data processing system (DPS) uses platform protection technology (PPT) to protect some or all of the code and data belonging to certain software modules. The PPT may include a virtual machine monitor (VMM) to enable an untrusted application and a trusted application to run on top of a single operating system (OS), while preventing the untrusted application from accessing memory used by the trusted application. The VMM may use a first extended page table (EPT) to translate a guest physical address (GPA) into a first host physical address (HPA) for the untrusted application. The VMM may use a second EPT to translate the GPA into a second HPA for the trusted application. The first and second EPTs may map the same GPA to different HPAs. Other embodiments are described and claimed.
    Type: Application
    Filed: September 30, 2022
    Publication date: February 2, 2023
    Applicant: Intel Corporation
    Inventors: Rajesh P. Banginwar, Sumanth Naropanth, Sunil K. Notalapati Prabhakara, Surendra K. Singh, Arvind Mohan, Ravi L. Sahita, Rahil Malhotra, Aman Bakshi, Vasudevarao Kamma, Jyothi Nayak, Vivek Thakkar, Royston A. Pinto
  • Publication number: 20230021214
    Abstract: Tracking of health and resilience of physical equipment and related systems are disclosed. A system includes physical equipment and one or more processors. The physical equipment includes one or more assets. The one or more processors are configured to determine a resilience metric for the physical equipment. The resilience metric includes a real power component and a reactive power component based, at least in part, on an aggregation of real components and reactive components of adaptive capacities of the one or more assets. A cyber-physical system includes physical equipment, network equipment configured to enable the physical equipment to communicate over one or more networks, a physical anomaly detection system (ADS) configured to detect anomalies in operation of the physical equipment and provide a physical component of a cyber-physical metric, and a cyber ADS configured to detect anomalies in network communications over the one or more networks.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 19, 2023
    Inventors: Jacob P. Lehmer, Craig G. Rieger, Bjorn C. Vaagensmith, Tyler B. Phillips, Timothy R. McJunkin, Robert C. Ivans, Vivek Kumar Singh, Justin J. Welch, Ruixuan Li, Daniel Marino Lizarazo, Chathurika Mudiyanselage Wickramasinghe Brahmana Mudiyanselage, Milos Manic, Brian Johnson
  • Patent number: 11545376
    Abstract: Embodiments of the present disclosure relate to a method and an apparatus for monitoring plasma behavior inside a plasma processing chamber. In one example, a method for monitoring plasma behavior includes acquiring at least one image of a plasma, and determining a plasma parameter based on the at least one image.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: January 3, 2023
    Assignee: Applied Materials, Inc.
    Inventors: Sidharth Bhatia, Edward P. Hammond, IV, Bhaskar Kumar, Anup Kumar Singh, Vivek Bharat Shah, Ganesh Balasubramanian
  • Publication number: 20220348921
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 3, 2022
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Patent number: 11467982
    Abstract: A data processing system (DPS) uses platform protection technology (PPT) to protect some or all of the code and data belonging to certain software modules. The PPT may include a virtual machine monitor (VMM) to enable an untrusted application and a trusted application to run on top of a single operating system (OS), while preventing the untrusted application from accessing memory used by the trusted application. The VMM may use a first extended page table (EPT) to translate a guest physical address (GPA) into a first host physical address (HPA) for the untrusted application. The VMM may use a second EPT to translate the GPA into a second HPA for the trusted application. The first and second EPTs may map the same GPA to different HPAs. Other embodiments are described and claimed.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: October 11, 2022
    Assignee: INTEL CORPORATION
    Inventors: Rajesh P. Banginwar, Sumanth Naropanth, Sunil K. Notalapati Prabhakara, Surendra K. Singh, Arvind Mohan, Ravi L. Sahita, Rahil Malhotra, Aman Bakshi, Vasudevarao Kamma, Jyothi Nayak, Vivek Thakkar, Royston A. Pinto
  • Patent number: 11421229
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 23, 2022
    Assignee: Baylor College of Medicine
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Publication number: 20220143142
    Abstract: Embodiments of the disclosure provide methods and compositions related to improving cardiomyocyte production by exposing starting cells to ETV2 and/or VEGF. The starting cells in specific embodiments are fibroblasts and/or endothelial cells, and following exposure to ETV2 and/or VEGF the resultant cells are exposed to one or more cardiomyocyte transdifferentiation factors, such as GATA4, myocyte enhancer factor-2c (Mef2c), T-box transcription factor 5 (TBX5), or a combination thereof. The produced cardiomyocytes are provided to individuals in need thereof, in particular embodiments.
    Type: Application
    Filed: March 17, 2020
    Publication date: May 12, 2022
    Inventors: Megumi Mathison, Todd Rosengart, Vivek P. Singh, Deepthi Sanagasetti, Jaya Pratap Pinnamaneni, Jianchang Yang
  • Publication number: 20180066252
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: February 19, 2016
    Publication date: March 8, 2018
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart